SAMHSA Announces More Than $281 Million in Funding Opportunities to Address Addiction, Overdose, and Mental Illness and Promote Recovery - Scorecard - MDSpire
Advertisement
SAMHSA Announces More Than $281 Million in Funding Opportunities to Address Addiction, Overdose, and Mental Illness and Promote Recovery
Clinical Scorecard: SAMHSA Unveils Over $281 Million in Grant Opportunities to Combat Addiction, Overdose, and Mental Health Issues While Supporting Recovery Efforts
At a Glance
Category
Detail
Condition
Substance Use Disorders and Mental Health Issues
Key Mechanisms
Funding for a range of behavioral health services including treatment, prevention, and recovery support.
Target Population
Individuals with substance use disorders, mental health issues, and their families.
Care Setting
Community-based behavioral health services
Key Highlights
$68.2 million for Medication-Assisted Treatment grants to expand access to opioid use disorder medications.
$55.7 million for Project AWARE grants to develop school-based mental health programs.
$40.6 million for National Child Traumatic Stress Initiative grants to provide trauma treatment for children.
$34.7 million for First Responders grants to train communities in opioid overdose reversal.
$10.5 million for Treatment, Recovery and Workforce Support grants for individuals in recovery.
Guideline-Based Recommendations
Diagnosis
Management
Expand access to evidence-based treatment for substance use disorders and mental health issues.
Monitoring & Follow-up
Risks
Potential for increased opioid misuse and overdose without proper community support and education.
Patient & Prescribing Data
Individuals with substance use disorders and mental health issues.
Focus on integrated care and community support to enhance recovery outcomes.
Clinical Best Practices
Implement trauma-informed care in treatment settings.
Promote collaboration between physical and behavioral health care providers.
Enhance mental health literacy and awareness in communities.
Longer initial prescriptions, use of multiple benzodiazepines, and long-acting agents were associated with delayed discontinuation in a retrospective population-based cohort study.
